A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease
Completed · Phase 2
Conditions studied: Dry Eye Disease
In brief
This is a Phase 2b, multicenter, vehicle-controlled, double-masked, randomized study. All subjects enrolled will have dry eye disease. The study consists of Screening and Baseline visits to determine eligibility, followed by efficacy assessments at Day 14 (Visit 3), 28 (Visit 4) and 84 (Visit 5/Study Exit). Safety will be assessed at all study visits.
Key facts
- Study ID
- NCT04498182
- Run by
- Aerie Pharmaceuticals
- People needed
- 369
- Starts
- 2020-10-26
- Expected to finish
- 2021-07-17
- Last updated by the study team
- 2024-08-28
Who can join
Age: 30 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cornea and Cataract Consultants of Arizona — Phoenix, Arizona, United States
- Eye Research Foundation — Newport Beach, California, United States
- Vision Institute — Colorado Springs, Colorado, United States
- Midwest Cornea Associates, LLC — Carmel, Indiana, United States
- Michael Washburn Center for Ophthalmic Research, LLC — Indianapolis, Indiana, United States
- The Eye Care Institute — Louisville, Kentucky, United States
- Andover Eye Associates — Andover, Massachusetts, United States
- Andover Eye Associates — Raynham, Massachusetts, United States
- Complete Eye Care of Medina — Hamel, Minnesota, United States
- Moyes Eye Center — Kansas City, Missouri, United States
- Vita Eye Clinic — Shelby, North Carolina, United States
- Total Eye Care, PA — Memphis, Tennessee, United States
- Advancing Vision Research, LLC — Smyrna, Tennessee, United States
- Alpine Research Organization, Inc, — Clinton, Utah, United States
- Piedmont Eye Center — Lynchburg, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.